ArticleAIDS (London, England)2019

Vedolizumab-mediated integrin α4β7 blockade does not control HIV-1SF162 rebound after combination antiretroviral therapy interruption in humanized mice.

Lijun Ling et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.